Podcast appearances and mentions of Robin L Jones

In this podcast episode, Jean-Yves Blay, MD, PhD, and Robin L. Jones, BSc, MBBS, MRCP, MD(Res), discuss the most important clinical trial data on leveraging TKIs as monotherapy and in combination with chemotherapy or immune checkpoint inhibitors for treatment of soft tissue sarcoma and osteosarcoma.Presenters:Jean-Yves Blay, MD, PhDProfessor of Medical OncologyDepartment of MedicineCentre Leon BerardLyon, FranceRobin L. Jones, BSc, MBBS, MRCP, MD(Res)ProfessorSarcoma UnitRoyal Marsden Hospital and Institute of Cancer ResearchLondon, United KingdomLink to full program, including accompanying downloadable slidesets:https://bit.ly/2ZL9bxq

Go online to PeerView.com/GVN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in tenosynovial giant cell tumors (TGCT) discuss recent advances in the understanding of tumor biology and the patterns of recurrent disease that have led to better awareness of diverse TGCT presentations, enhanced diagnostic and prognostic models, and an overall improvement in patient care. Upon completion of this activity, participants should be better able to: Discuss the clinical signs and symptoms of localized and diffuse TGCT, including recurrent disease, Summarize the range of challenging clinical presentations of TGCT, including settings in which surgical resection is likely not a therapeutic option, Develop strategies for accurate diagnostic assessment of TGCT, including for localized and diffuse disease, Select patient-appropriate multimodal management strategies for TGCT in collaboration with the multidisciplinary team.

Go online to PeerView.com/GVN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in tenosynovial giant cell tumors (TGCT) discuss recent advances in the understanding of tumor biology and the patterns of recurrent disease that have led to better awareness of diverse TGCT presentations, enhanced diagnostic and prognostic models, and an overall improvement in patient care. Upon completion of this activity, participants should be better able to: Discuss the clinical signs and symptoms of localized and diffuse TGCT, including recurrent disease, Summarize the range of challenging clinical presentations of TGCT, including settings in which surgical resection is likely not a therapeutic option, Develop strategies for accurate diagnostic assessment of TGCT, including for localized and diffuse disease, Select patient-appropriate multimodal management strategies for TGCT in collaboration with the multidisciplinary team.

Go online to PeerView.com/GVN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in tenosynovial giant cell tumors (TGCT) discuss recent advances in the understanding of tumor biology and the patterns of recurrent disease that have led to better awareness of diverse TGCT presentations, enhanced diagnostic and prognostic models, and an overall improvement in patient care. Upon completion of this activity, participants should be better able to: Discuss the clinical signs and symptoms of localized and diffuse TGCT, including recurrent disease, Summarize the range of challenging clinical presentations of TGCT, including settings in which surgical resection is likely not a therapeutic option, Develop strategies for accurate diagnostic assessment of TGCT, including for localized and diffuse disease, Select patient-appropriate multimodal management strategies for TGCT in collaboration with the multidisciplinary team.

Go online to PeerView.com/GVN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in tenosynovial giant cell tumors (TGCT) discuss recent advances in the understanding of tumor biology and the patterns of recurrent disease that have led to better awareness of diverse TGCT presentations, enhanced diagnostic and prognostic models, and an overall improvement in patient care. Upon completion of this activity, participants should be better able to: Discuss the clinical signs and symptoms of localized and diffuse TGCT, including recurrent disease, Summarize the range of challenging clinical presentations of TGCT, including settings in which surgical resection is likely not a therapeutic option, Develop strategies for accurate diagnostic assessment of TGCT, including for localized and diffuse disease, Select patient-appropriate multimodal management strategies for TGCT in collaboration with the multidisciplinary team.

Go online to PeerView.com/GVN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in tenosynovial giant cell tumors (TGCT) discuss recent advances in the understanding of tumor biology and the patterns of recurrent disease that have led to better awareness of diverse TGCT presentations, enhanced diagnostic and prognostic models, and an overall improvement in patient care. Upon completion of this activity, participants should be better able to: Discuss the clinical signs and symptoms of localized and diffuse TGCT, including recurrent disease, Summarize the range of challenging clinical presentations of TGCT, including settings in which surgical resection is likely not a therapeutic option, Develop strategies for accurate diagnostic assessment of TGCT, including for localized and diffuse disease, Select patient-appropriate multimodal management strategies for TGCT in collaboration with the multidisciplinary team.

Go online to PeerView.com/GVN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in tenosynovial giant cell tumors (TGCT) discuss recent advances in the understanding of tumor biology and the patterns of recurrent disease that have led to better awareness of diverse TGCT presentations, enhanced diagnostic and prognostic models, and an overall improvement in patient care. Upon completion of this activity, participants should be better able to: Discuss the clinical signs and symptoms of localized and diffuse TGCT, including recurrent disease, Summarize the range of challenging clinical presentations of TGCT, including settings in which surgical resection is likely not a therapeutic option, Develop strategies for accurate diagnostic assessment of TGCT, including for localized and diffuse disease, Select patient-appropriate multimodal management strategies for TGCT in collaboration with the multidisciplinary team.

Go online to PeerView.com/CSD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. PeerView's latest online activity, based on a live symposium held adjunct to the CTOS 2020 Annual Meeting CTOS in Tokyo, addresses the newest treatment developments for rare and typically benign, tenosynovial giant cell tumor (TGCT), and provides a multidisciplinary look at how novel targeted therapeutics have enhanced the long-standing treatment landscape. This intimate, mentor-based, CME/MOC/CC-certified activity sheds light on a historically difficult-to-treat connective tissue tumor and the science that is providing hope for patients with TGCT. Don't miss this unique educational opportunity. Upon completion of this activity, participants should be better able to: Discuss the clinical signs and aggressive course of rare connective tissue tumors, including tenosynovial giant cell tumor, Cite the biologic rationale and clinical evidence for the use of targeted options in the management of rare connective tissue tumors, Develop multidisciplinary approaches for the recognition and treatment of connective tissue tumors, including rare nonmalignant disorders

Go online to PeerView.com/CSD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. PeerView's latest online activity, based on a live symposium held adjunct to the CTOS 2020 Annual Meeting CTOS in Tokyo, addresses the newest treatment developments for rare and typically benign, tenosynovial giant cell tumor (TGCT), and provides a multidisciplinary look at how novel targeted therapeutics have enhanced the long-standing treatment landscape. This intimate, mentor-based, CME/MOC/CC-certified activity sheds light on a historically difficult-to-treat connective tissue tumor and the science that is providing hope for patients with TGCT. Don't miss this unique educational opportunity. Upon completion of this activity, participants should be better able to: Discuss the clinical signs and aggressive course of rare connective tissue tumors, including tenosynovial giant cell tumor, Cite the biologic rationale and clinical evidence for the use of targeted options in the management of rare connective tissue tumors, Develop multidisciplinary approaches for the recognition and treatment of connective tissue tumors, including rare nonmalignant disorders

Go online to PeerView.com/CSD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. PeerView's latest online activity, based on a live symposium held adjunct to the CTOS 2020 Annual Meeting CTOS in Tokyo, addresses the newest treatment developments for rare and typically benign, tenosynovial giant cell tumor (TGCT), and provides a multidisciplinary look at how novel targeted therapeutics have enhanced the long-standing treatment landscape. This intimate, mentor-based, CME/MOC/CC-certified activity sheds light on a historically difficult-to-treat connective tissue tumor and the science that is providing hope for patients with TGCT. Don't miss this unique educational opportunity. Upon completion of this activity, participants should be better able to: Discuss the clinical signs and aggressive course of rare connective tissue tumors, including tenosynovial giant cell tumor, Cite the biologic rationale and clinical evidence for the use of targeted options in the management of rare connective tissue tumors, Develop multidisciplinary approaches for the recognition and treatment of connective tissue tumors, including rare nonmalignant disorders

Go online to PeerView.com/CSD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. PeerView's latest online activity, based on a live symposium held adjunct to the CTOS 2020 Annual Meeting CTOS in Tokyo, addresses the newest treatment developments for rare and typically benign, tenosynovial giant cell tumor (TGCT), and provides a multidisciplinary look at how novel targeted therapeutics have enhanced the long-standing treatment landscape. This intimate, mentor-based, CME/MOC/CC-certified activity sheds light on a historically difficult-to-treat connective tissue tumor and the science that is providing hope for patients with TGCT. Don't miss this unique educational opportunity. Upon completion of this activity, participants should be better able to: Discuss the clinical signs and aggressive course of rare connective tissue tumors, including tenosynovial giant cell tumor, Cite the biologic rationale and clinical evidence for the use of targeted options in the management of rare connective tissue tumors, Develop multidisciplinary approaches for the recognition and treatment of connective tissue tumors, including rare nonmalignant disorders

Go online to PeerView.com/CSD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. PeerView's latest online activity, based on a live symposium held adjunct to the CTOS 2020 Annual Meeting CTOS in Tokyo, addresses the newest treatment developments for rare and typically benign, tenosynovial giant cell tumor (TGCT), and provides a multidisciplinary look at how novel targeted therapeutics have enhanced the long-standing treatment landscape. This intimate, mentor-based, CME/MOC/CC-certified activity sheds light on a historically difficult-to-treat connective tissue tumor and the science that is providing hope for patients with TGCT. Don't miss this unique educational opportunity. Upon completion of this activity, participants should be better able to: Discuss the clinical signs and aggressive course of rare connective tissue tumors, including tenosynovial giant cell tumor, Cite the biologic rationale and clinical evidence for the use of targeted options in the management of rare connective tissue tumors, Develop multidisciplinary approaches for the recognition and treatment of connective tissue tumors, including rare nonmalignant disorders

Go online to PeerView.com/CSD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. PeerView's latest online activity, based on a live symposium held adjunct to the CTOS 2020 Annual Meeting CTOS in Tokyo, addresses the newest treatment developments for rare and typically benign, tenosynovial giant cell tumor (TGCT), and provides a multidisciplinary look at how novel targeted therapeutics have enhanced the long-standing treatment landscape. This intimate, mentor-based, CME/MOC/CC-certified activity sheds light on a historically difficult-to-treat connective tissue tumor and the science that is providing hope for patients with TGCT. Don't miss this unique educational opportunity. Upon completion of this activity, participants should be better able to: Discuss the clinical signs and aggressive course of rare connective tissue tumors, including tenosynovial giant cell tumor, Cite the biologic rationale and clinical evidence for the use of targeted options in the management of rare connective tissue tumors, Develop multidisciplinary approaches for the recognition and treatment of connective tissue tumors, including rare nonmalignant disorders

Go online to PeerView.com/CSD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. PeerView's latest online activity, based on a live symposium held adjunct to the CTOS 2020 Annual Meeting CTOS in Tokyo, addresses the newest treatment developments for rare and typically benign, tenosynovial giant cell tumor (TGCT), and provides a multidisciplinary look at how novel targeted therapeutics have enhanced the long-standing treatment landscape. This intimate, mentor-based, CME/MOC/CC-certified activity sheds light on a historically difficult-to-treat connective tissue tumor and the science that is providing hope for patients with TGCT. Don't miss this unique educational opportunity. Upon completion of this activity, participants should be better able to: Discuss the clinical signs and aggressive course of rare connective tissue tumors, including tenosynovial giant cell tumor, Cite the biologic rationale and clinical evidence for the use of targeted options in the management of rare connective tissue tumors, Develop multidisciplinary approaches for the recognition and treatment of connective tissue tumors, including rare nonmalignant disorders

Go online to PeerView.com/CSD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. PeerView's latest online activity, based on a live symposium held adjunct to the CTOS 2020 Annual Meeting CTOS in Tokyo, addresses the newest treatment developments for rare and typically benign, tenosynovial giant cell tumor (TGCT), and provides a multidisciplinary look at how novel targeted therapeutics have enhanced the long-standing treatment landscape. This intimate, mentor-based, CME/MOC/CC-certified activity sheds light on a historically difficult-to-treat connective tissue tumor and the science that is providing hope for patients with TGCT. Don't miss this unique educational opportunity. Upon completion of this activity, participants should be better able to: Discuss the clinical signs and aggressive course of rare connective tissue tumors, including tenosynovial giant cell tumor, Cite the biologic rationale and clinical evidence for the use of targeted options in the management of rare connective tissue tumors, Develop multidisciplinary approaches for the recognition and treatment of connective tissue tumors, including rare nonmalignant disorders